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Abstract
Deregulated apoptosis is the hall mark of many cancers, therefore every defect in apoptosis pathway could be a potential target
for cancer treatment.The anticancer mechanism of limonene could be multifactorial. However, induction of apoptosis in cancer
cells is proposed as the predominant mechanism in several of preclinical studies. Therefore, we determined to investigate the
role of apoptosis in the anticancer activity of limonene and BEZ235 combination in COLO-320 and HCT-116 colon cancer cells.
Cells after treatments were assessed for apoptosis by DAPI staining for fluorescent microscopic examination of apoptotic cells,
estimation of caspases activities, Bcl-2 family proteins in addition to cell cycle analysis by flowcytometry. Results show that both
drugs induced apoptosis as demonstrated by increased caspases activity, significant alterations in pro and anti-apoptotic proteins
of Bcl-2 family in promoting apoptosis and cell cycle arrest at G1 phase. Over all, it is indicated that limonene and BEZ exerted
anticancer activity is mediated through induction of apoptosis involving mitochondria mediated intrinsic death pathway in the
selected CRC cells.
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Introduction
Apoptosis or programmed cell death is an essential physiologi-
cal process and an underlying cause of many diseases including
cancer. There are two pathways by which it is activated such
as extrinsic and intrinsic pathways of apoptosis. Extrinsic path-
way is initiated by binding of death ligands to death receptors,
whereas, intrinsic pathway is initiated due to stimuli such as ge-
netic damage, hypoxia and severe oxidative stress and is reg-
ulated by Bcl-2 family proteins [1]. Apoptosisis characterized
by series of morphological changes and activation of specific
group of enzymes namely caspases leading to cleavage of nu-
clear and cytoskeleton scaffold [2]. As deregulated apoptosis is
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the hall mark of many cancers, thus every defect or deregulation
in apoptosis pathway can be a potential target for cancer treat-
ment and many of such apoptosis based therapeutic strategies
are under development [3]. D-limonene is a dietary monoter-
pene abundantly present in several citrus oils [4]. It is shown to
have wide clinical applications in cancer as well as in other dis-
ease conditions. The anticancer mechanism of limonene could
be multifactorial. Several of preclinical studies indicate that in-
duction of apoptosis in cancer cells could be one of the most
important mechanisms for its anticancer activity [5]. NVP-BEZ
235 is a dual pan-class I PI3K and mTOR kinase inhibitor and
is currently in clinical trials against solid tumors [6]. Addition-
ally, the diverse mechanisms proposed for its clinical efficacy
including induction of apoptosis, autophagy, impair DNA repair
mechanisms, increase of radio sensitivity and cell cycle arrest.
The anticancer activity of limonene is modest when used alone,
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hence it is proposed to use in combination with BEZ in a bid to
explore better efficacy compared to monotherapy.
Human colorectal cancer (CRC) cells COLO-320 (wt-K-ras
and PI3K) and HCT-116 (mt-K-ras and PI3K) have been cho-
sen to study the role of apoptosis in the anticancer activity of
limonene and BEZ 235 combination using in vitro anticancer
tests. In general, K-ras and PI3K mutations are used as valid
biomarkers in the clinical management of CRC, and also a sig-
nificant proportion of human tumors display coexisting muta-
tions of these pathways leading to poor prognosis. In addition,
CRCs are considered as the most resistant type because of their
constant exposure to ingested food and toxins and thus CRC
cells are considered as an ideal model for representing clinical
cancer drug resistance. Therefore, testing the drug combination
in selected CRC cells may explore the clinical utility of the drug
combination even against resistant cancer phenotypes.
Material and Methods
Cell lines and drugs
COLO-320 and HCT-116 colon cancer cell lines were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA), and was maintained in DMEM culture medium (Gibco
BRL-Invitrogen) supplemented with 10% FBS (Hi-Media), 100
U/ml penicillin and 100 µg/ml streptomycin (Hi-Media) at 37o
C in an incubator with 5% CO2. D-Limonene was procured from
Sigma and NVP-BEZ235 (Novartis) was procured from Cayman
chemicals (Prolab Marketing Pvt Ltd, New Delhi, India).
DAPI staining for fluorescent microscopic examination of
apoptotic cells
Cells (1×105/well) in 6 well culture plates were treated with
limonene and BEZ alone and with their combinations for 48h.
Cells were harvested, washed 3x in PBS and fixed in 3.7%
formaldehyde in PBS for 10min at room temperature. The fix-
ative was removed and the cells were washed 3x, 5min each in
PBS and incubated with 0.1% Triton X-100 (Sigma) for 5min, to
make the cells permeable. The cells were washed 3x in PBS and
incubated with DAPI (Sigma) staining solution (stock=1mg/ml
in dH2O -diluted 1:1000 in PBS before use) for 10min at room
temperature in the dark; washed 3x in PBS and mounted with
cover slip and examined under fluorescent microscope with blue
filter. The slides were screened for the quantification of cells
showing features of apoptosis, and were expressed as % apop-
totic cells [7].
Estimation of caspases-3 and -9 activities
The activities of caspases-3 and 9 were measured using col-
orimetric assay kit [8]. The assay is based on spectrophoto-
metric detection of the chromophore p-nitroaniline (pNA) after
cleavage from the labeled substrate DEVD-pNA (caspase 3) and
LEHD-pNA (caspase 9). The pNA light emission from the re-
spective substrates can be quantified using a spectrophotome-
ter. Cells (1×106) in 25cm2 flask were treated with limonene,
BEZ and also with their combinations for 48h. Cells were har-
vested and suspended in 50µl of chilled lysis buffer for 10min
and centrifuged at 10000x g for 1min and the supernatant was
transferred to a fresh tube for protein quantification. Approxi-
mately, 100µg protein was diluted in 50µl lysis buffer for each
assay. Then to each sample, 50µl of 2X reaction buffer contain-
ing 10mM DTT and 5µl of 4mM DEVD-pNA (for caspase 3)
and 4mM LEHD- pNA (for caspase 9) substrates were added and
incubated at 37oC for 2h. The OD was measured at 400nm in a
plate reader (BioTEK, synergy 4 multimode microplate reader).
Increase in number of fold of caspase activity of test samples was
determined by comparing the results with the untreated control.
Effect of limonene and BEZ combination on regulation of
Bcl-2 family proteins
Cells (1×106) following treatments were washed with ice cold
PBS, lysed with ice cold RIPA buffer containing protease in-
hibitor cocktail (RIPA + PI - 1ml+40µl) (Roche, Indianapolis,
IN, USA) and centrifuged at 12000x g for 15min at 4ºC. Su-
pernatants were collected and total protein quantification was
performed with Bio-Rad protein assay kit (Bio-Rad Labora-
tories, Munich, Germany). Equal amounts (40µg) of protein
were fractionated by performing 8% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad) and
transferred to nitrocellulose membranes. The membranes were
blocked for 1h at room temperature with fresh 5% non-fat
dried milk in TBST (10mMTris, 150mMNaCl, 0.5% Tween-
20; pH7.4) and incubated with primary antibodies (1:1000) from
Cell Signaling Technology (Beverly, MA) overnight at 4ºC. The
antibodies used were against; BAD, BAX, Bcl-2 and β-actin.
The membranes were washed three times with TBST and in-
cubated with goat anti-rabbit or anti mouse IgG conjugated sec-
ondary antibody (Cell Signaling Technology, 1:5000 dilutions in
5% non fat milk in TBST) for 1h at room temperature. Following
washing with TBST buffer, the protein bands were developed us-
ing enhanced chemiluminescence kit (ECL, Bio-Rad) according
to the manufacturer’s instructions [9].
Cell cycle analysis by Flow cytometry
The cell cycle analysis was performed to evaluate the distri-
bution of cells in different phases. Asynchronized cells were
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seeded (1×106) in 25cm2 flask. Following after overnight incu-
bation, the cells were treated with limonene, BEZ alone and also
with combinations for 48h. The cells were harvested, washed
with cold PBS and fixed in ice-cold 70% ethanol and kept at
-20ºC for 24 –48h. Before the analysis, the cells were washed
with cold PBS and then suspended in PBS containing DNAse
free-RNAse A (420µg/ml, Bio-medicals, LLC, France) at 37ºC
for 30min and stained with propidium iodide (1µg/ml, BD
PharmingenTM). The samples were analyzed by flow cytome-
try using BD LSRFortessaTM cell analyzer instrument (BD Bio-
science, San Jose, CA, USA) and the results were analyzed
using BD FACSDivasoftware (BD Biosciences, San Jose, CA,
USA) to determine the percentage distribution of cells in dif-
ferent phases for untreated and drug treated groups of each cell
line [10].
Statistical analysis
Statistical analysis was carried out using ‘GraphPad Prism Soft-
ware’ version 5.0 (San Diego, USA). All the experiments were
performed in triplicate. Data were presented as mean± standard
deviation (SD) and analyzed by one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison test. The
level of significance was set at p < 0.05.
Results & Discussion
Results
Limonene and BEZ induce apoptosis in colorectal cancer
cells
Both the drugs exhibited significant increase in apoptosis com-
pared to corresponding untreated control (p< 0.05). In COLO-
320 cells the % apoptotic cells for limonene (1000 µM), BEZ
(100 nM) and their combination treatment were 20%, 16.3%
and 32.7% respectively. Similarly, the % apoptotic cells in HCT-
116 cells treated with limonene (2000 µM), BEZ (100 nM) and
their combination were 18%, 16.7% and 27% respectively. Drug
combination was more effective than either agent alone (Fig 1).
COLO-320 cells appear to be more sensitive to apoptosis than
HCT-116 possibly because of wild type expressions of the PI3K
and K-ras signaling pathways in the former cell line.
Effects on caspases-3 and -9 activities
The cells were treated and fold increase in caspase activities
were estimated by comparing to those of untreated control (Fig
2). The activities of both the caspases were significantly in-
creased (p< 0.05) by combination treatment, whereas, individu-
ally only limonene showed significant increase in the caspase-3
in both the cells.
Figure 1 Effect of limonene and BEZ combination on apoptosis in
COLO-320 and HCT-116 cells. Cells following treatment were
stained with DAPI and examined under fluorescent microscope for
quantification of apoptotic cells (%). Data were expressed as mean
± SD (n=3).*p < 0.05
In COLO-320 cells, treatment with limonene (1000 µM),
BEZ (100nM) and their combination showed 1.5x, 1.4x and 1.7
fold increase in caspase-3 activity and 1.4x, 1.1x and 1.5 fold
increase in caspase-9 activity respectively. Whereas, in HCT-
116 cells, treatment with limonene (2000 µM), BEZ (100 nM)
and their combination showed 1.5x, 1.3x and 1.6 fold increase
in caspase-3 activity and 1.1x, 1.1x and 1.3 fold increase in
caspase-9 activity respectively.
Figure 2 Effect of drug combination on caspase-3 and -9 activities.
Cells were treated for 48 h and caspase activity was measured by
colorimetric method. OD values of treated were compared with
control to determine the fold increase in caspase activity. Data were
presented as mean ± SD (n=3). *p < 0.05
Limonene and BEZinduce apoptosis by regulation of Bcl-2
family proteins
Western blot analysis was performed and the proteins were quan-
tified to determine the combination effect on the expression of
pro and anti-apoptotic proteins. Drug treatments exhibited sig-
nificant alterations in the expression of proteins compared to
untreated control (Fig 3). In COLO-320 cells, treatment with
limonene (1000 µM), BEZ (100 nM) and their combination re-
spectively resulted 1.4x, 1.5x and 1.7 fold increase in the ex-
pression of BAD and 3.5x, 4.2x and 4.7 fold increase in BAX
with a concomitant decrease of 0.4x, 0.9x and 0.9 fold in the
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expression of Bcl-2 (p< 0.05). Whereas, HCT-116 cells treated
with limonene (2000 µM) did not significantly alter the pro- and
anti-apoptotic proteins, but treatment with BEZ (100 nM) and
combination showed an increase of 1.3x and 1.5 fold respec-
tively in BAD with a concomitant decrease of Bcl-2 by 0.6 fold
(p< 0.05). However, the expression of BAX was significantly
increased (1.3x) following combination treatment without much
responsive to the drugs individually.
Figure 3 Western blot analysis showing the effect of drug treatment
on expression of pro and anti-apoptotic proteins of Bcl-2 family in
COLO-320 (A) and HCT-116 (B) cells. β-Actin was used as loading
control.
Combination effect on distribution of cell cycle phases
In general, there is a high potential for cells in G2 phase to en-
ter into the mitosis for proliferation and eventually become tu-
morigenic. However, when the combination effects on cell cycle
phases were analyzed, it clearly showed a significant increase in
G1 phase cells compared to respective control, indicating that
G1 phase might be the target for both the drugs (Fig 4). Conse-
quently, there were very few cells in G2 phase that can enter in
mitosis phase, indicating the profound antiproliferative effects
of the combination.
Discussion
CRC is the third most common cancer with significant mor-
tality and morbidity. As they develop due to multiple genetic
alterations or abnormalities, it is seldom possible to treat with
monotherapy.Therefore, current chemotherapy practices employ
combination of anticancer agents to obtain clinical efficacy. In-
duction of apoptosis in cancer cells is the most effective ap-
proach for clinical regression of tumors. Therefore, we designed
the study to determine the role of apoptosis in the anticancer
activity of limonene and BEZ combination in the CRC cells se-
lected. In earlier studies we demonstrated the synergistic inter-
action of limonene and BEZ combination effects on inhibition
of cell viability, migration and clonogenicity in the same cancer
cells [11].
DAPI is a cell permeable fluorescent DNA binding dye that
enables microscopic detection of apoptotic cells based on fea-
tures such as, cell shrinkage, nuclear condensation and fragmen-
tation. COLO-320 cells (32.7%) were found to be highly sensi-
tive to the combination induced apoptosis than HCT-116 (27%)
possibly because of marked genetic variations. In leukemia,
prostate cancer cells and human gastric cancer implanted in nude
mice also, limonene exerted anticancer activity that was medi-
ated through induction of apoptosis [12]. Similarly, BEZ also
induced apoptosis in breast, colon and glioma stem cells, sug-
gesting that apoptosis pathway could be the main target for both
the drugs in the tested CRC cells.
Caspases are cysteine-aspartic acid protease family enzymes
that are key players in the apoptotic mechanism. However, muta-
tions in caspase genes are not as frequent as p53 mutations, em-
phasizing the critical role they play in apoptosis [13]. Therefore,
we estimated the caspases activities in order to identify the un-
derlying mechanism for increased apoptosis. Results show that,
the combination was more efficacious for induction of caspase-3
activity than caspase-9 in both the cells, which is strongly cor-
roborating with antiproliferative activity of the combination, as
caspase-3 is an effector caspase. Because of its critical role in
apoptosis, compounds have been developed capable of directly
activating caspase-3 for use in cancer therapy [14, 15] or in-
directly activate caspases by blocking endogenous caspase in-
hibitors [16].
Although the caspases mediated proteolytic cascade repre-
sents a central point in the apoptotic pathway, its initiation is
closely regulated upstream by Bcl-2 family proteins. Therefore,
further experiments were intended to determine the effects of
drugs on regulation of pro-apoptotic (BAD and BAX) and anti-
apoptotic (Bcl-2) proteins of Bcl-2 family in order to promote re-
lease of cytochrome c from mitochondria, eventually, activating
downstream caspase cascade [17]. As the ratio of BAX to Bcl-2
determines whether a cell should undergo apoptosis or not, the
drug combination clearly altered the balance by not only increas-
ing the BAX ratio, but also causing a significant decline in Bcl-2.
Further, the results clearly indicate that limonene and BEZ com-
bination increased the activity of BAD, which in part, might be
due to their ability to down regulate survival promoter AKT ac-
tivity, therefore, alleviating the phosphorylation and inactivation
of BAD by AKT [18]. The effects of limonene on Bcl-2 fam-
ily members were widely investigated in various types of cancer
cells, our results are in agreement with those studies highlighting
that mitochondrial death pathway could be the potential target
for drug effects in CRC cells tested. As stated before COLO-
320 cells were more sensitive to the induction of apoptosis pos-
sibly because of significant alterations in BAX (high increase)
and Bcl-2 (high decrease) compared to HCT-116 cells.
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Figure 4 Flow cytometric analysis for combination effects of limonene and BEZ on distribution of cells in different phases of cell cycle in
COLO-320 (A) and HCT-116(B) cells. The percentage of cells in each phase of cell cycle (G1, S and G2) is indicated.
Conclusions
The anticancer activity of limonene and BEZ combination in
CRC cells tested was shown to be mediated through induction of
apoptosis involving mitochondria mediated intrinsic death path-
way as demonstrated by increased caspases activity and alter-
ations of pro and anti-apoptotic proteins of Bcl-2 family in pro-
moting apoptosis.
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